gilead 1st qtr earnings webcast this tuesday, page-7

this is actually true i have to agree with tooluck
However even at a maximum output of 190m doses pa gsk would still be short of production should govt continue to move toward rebalancing the stockpile - replacing expiring product and dealing with resistance to tamiflu and other contingencies. so regardless of production/sales for the next few quarters these fundamentals are not going to change anytime soon.if anything the long term production of relenza must go up until lani comes online